Brukinsa 80mg Price UAE | Ernest Oncology International Distributor

Brukinsa 80mg Capsule: Next-Generation BTK Inhibitor for B-Cell Malignancies

Are you looking for a trusted Brukinsa 80 mg capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading global supplier and bulk distributor of advanced hematology-oncology treatments. We provide reliable supply chains to the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, ensuring that life-saving BTK inhibitors reach healthcare providers and pharmacies efficiently.

Detailed Product Overview: What is Brukinsa 80mg?

Brukinsa 80 mg is a potent, small-molecule inhibitor containing the active ingredient Zanubrutinib. It belongs to a sophisticated class of drugs known as Bruton’s Tyrosine Kinase (BTK) Inhibitors.

Unlike first-generation inhibitors, Zanubrutinib was specifically designed to be more selective, maximizing the occupancy of the BTK protein while minimizing "off-target" binding to other kinases. This high selectivity often results in better tolerability and reduced side effects for patients undergoing long-term treatment for blood cancers.

Primary Therapeutic Indications:

Brukinsa 80mg is clinically indicated for several B-cell malignancies, including:

• Waldenström’s Macroglobulinemia (WM): A rare type of slow-growing non-Hodgkin lymphoma.

• Mantle Cell Lymphoma (MCL): For adult patients who have received at least one prior therapy.

• Marginal Zone Lymphoma (MZL): For relapsed or refractory cases after at least one anti-CD20-based regimen.

• Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Providing a critical treatment option for both newly diagnosed and previously treated patients.  

Mechanism of Action: How Brukinsa Works: 

Brukinsa functions by interrupting the survival signals that B-cells rely on to multiply and spread.

1. BTK Binding: Zanubrutinib forms a covalent bond with the BTK enzyme, which is a crucial part of the B-cell receptor (BCR) signaling pathway.

2. Signal Interruption: By blocking BTK, the drug shuts down the signals that tell the malignant B-cells to grow and survive.

3. Inhibition of Proliferation: This leads to a decrease in tumor cell migration and adhesion and eventually causes the death of the cancerous B-cells.

Administration and Dosage: 

• Route: Administered orally as a capsule.

• Dosage: The standard dose is typically 320mg daily (taken as four 80mg capsules once a day or two 80mg capsules twice a day).

• Flexibility: Capsules can be taken with or without food but should be swallowed whole with water.

Clinical Side Effects & Safety Monitoring:

While generally well-tolerated, healthcare providers monitor for:

• Neutropenia: Decreased white blood cell counts.

• Hemorrhage: Increased risk of bleeding or bruising.

• Atrial Fibrillation: Monitoring heart rhythm for irregularities.

• Second Primary Malignancies: Regular skin checks for potential non-melanoma skin cancers.

Why source Brukinsa 80 mg from Ernest Oncology?

• Global Export Compliance: We handle all international regulatory requirements for shipping to the USA, UK, UAE, Australia, and South Africa. 

• Bulk Availability: Consistent stock of 80mg capsules ensures that global distributors can fulfill hospital tenders and pharmacy orders without delay.

• Authenticity Guaranteed: Direct sourcing from certified facilities, maintaining the integrity of every exporter from India shipment.

• Logistics Excellence: Professional packaging and track-and-trace capabilities for secure international transit.